Nj State Employees Deferred Compensation Plan Arrowhead Pharmaceuticals, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $877 Million
- Q3 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 10,500 shares of ARWR stock, worth $411,914. This represents 0.04% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$411,914
Previous $165,000
119.39%
% of portfolio
0.04%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding ARWR
# of Institutions
331Shares Held
100MCall Options Held
444KPut Options Held
568K-
Vanguard Group Inc Valley Forge, PA16MShares$629 Million0.01% of portfolio
-
Black Rock Inc. New York, NY15.7MShares$615 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.6MShares$416 Million3.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$250 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$205 Million1.65% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $4.15B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...